DeNardo GL - Search Results

1

Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.

Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Rose LM, et al. Among authors: denardo sj, denardo gl. Cancer Immunol Immunother. 1996 Sep;43(1):26-30. doi: 10.1007/s002620050299. Cancer Immunol Immunother. 1996. PMID: 8917632

2

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.

Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, Meares CF. Kukis DL, et al. Among authors: denardo sj, denardo gl. Cancer Res. 1995 Feb 15;55(4):878-84. Cancer Res. 1995. PMID: 7850803

3

Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia.

DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. DeNardo GL, et al. Among authors: denardo sj. Cancer. 1994 Mar 1;73(5):1425-32. doi: 10.1002/1097-0142(19940301)73:5<1425::aid-cncr2820730517>3.0.co;2-d. Cancer. 1994. PMID: 8111709 Clinical Trial.

4

Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).

DeNardo GL, Kukis DL, Shen S, Mausner LF, Meares CF, Srivastava SC, Miers LA, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Clin Cancer Res. 1997 Jan;3(1):71-9. Clin Cancer Res. 1997. PMID: 9815540

5

Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.

Kroger LA, DeNardo SJ, DeNardo GL, Xiong CY, Winthrop MD, Gumerlock PH. Kroger LA, et al. Among authors: denardo sj, denardo gl. Clin Cancer Res. 1999 Oct;5(10 Suppl):3010s-3014s. Clin Cancer Res. 1999. PMID: 10541336

6

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ. O'Donnell RT, et al. Among authors: denardo sj, denardo gl. Clin Cancer Res. 1999 Oct;5(10 Suppl):3330s-3336s. Clin Cancer Res. 1999. PMID: 10541382 Clinical Trial.

7

Critical Lym-1 binding residues on polymorphic HLA-DR molecules.

Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, DeNardo GL, Meares CF. Rose LM, et al. Among authors: denardo gl. Mol Immunol. 1999 Aug;36(11-12):789-97. doi: 10.1016/s0161-5890(99)00083-8. Mol Immunol. 1999. PMID: 10593517 No abstract available.

8

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.

DeNardo GL, Mirick GR, Hok S, DeNardo SJ, Beckett LA, Adamson GN, Balhorn RL. DeNardo GL, et al. Int J Oncol. 2009 Feb;34(2):511-6. Int J Oncol. 2009. PMID: 19148487

9

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.

Albrecht H, Cosman M, Ngu-Schwemlein M, Corzett M, Curran KW, Dolan C, Fang X, DeNardo SJ, DeNardo GL, Balhorn R. Albrecht H, et al. Among authors: denardo sj, denardo gl. Cancer Biother Radiopharm. 2007 Aug;22(4):531-42. doi: 10.1089/cbr.2007.375A. Cancer Biother Radiopharm. 2007. PMID: 17803448

10

Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.

Balhorn R, Hok S, Burke PA, Lightstone FC, Cosman M, Zemla A, Mirick G, Perkins J, Natarajan A, Corzett M, DeNardo SJ, Albrecht H, Gregg JP, DeNardo GL. Balhorn R, et al. Among authors: denardo sj, denardo gl. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5621s-5628s. doi: 10.1158/1078-0432.CCR-07-1128. Clin Cancer Res. 2007. PMID: 17875798

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

517 results

Search Page